NCT01087970 · REGISTRY CONDITION SEARCH

A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2014-05-19

The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell carcinoma of the head and neck.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Progression-Free Survival (PFS)

→

outcome · POSTED

Overall Survival (OS)

→

outcome · POSTED

Percentage of Participants Having a Confirmed Partial Response (PR) or Complete Response (CR)

→

outcome · POSTED

Change From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L)

→

outcome · POSTED

Change From Baseline in Performance Status Scale for Head and Neck Cancer (PSS-HNC)

→

outcome · POSTED

Number of Participants Who Died While on Treatment and Died During 30-Day Post-Treatment Discontinuation Follow-Up (FU)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Histologic or cytologic diagnosis of squamous cell head and neck cancer (HNC) * Recurrent disease (locally advanced or metastatic) that is not amenable to local therapy, (i) with at least 6 months since completion of systemic therapy (chemotherapy or biological anticancer therapy), and (ii) with no more than 1 prior multimodal therapy (such as concurrent chemoradiation with or without sequential chemotherapy) for locally advanced HNC tumor, and (iii) with no prior systemic therapy (chemotherapy or biological anticancer therapy) for metastatic disease; OR * Newly diagnosed distant metastatic disease (Stage IVc) * Prior therapies: * Radiation therapy must be completed at least 4 weeks before study enrollment. For palliative therapy, prior radiation therapy allowed \<25% of the bone marrow and prior radiation to the whole pelvis is not allowed. Participants must have recovered from the acute toxic effects of the treatment prior to study enrollment. * Surgery (excluding prior diagnostic biopsy) must be completed at least 4 weeks before study enrollment. Participants must have fully recovered from any acute effects of surgery prior to study enrollment. * An estimated life expectancy of at least 12 weeks. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * Biological tissue available for biomarker analysis on tumor tissue. * Disease status must be measurable as defined by Response Evaluation Criteria in Solid Tumors (RECIST). The index lesion must not be in a prior irradiated area. Positron emission tomography (PET) scans and ultrasounds may not be used for lesion measurements. * Participant compliance and geographic proximity that allow for adequate follow-up. * Adequate organ function as defined by the following: * Bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) greater than or equal to 1.5 × 10⁹/liter (L), platelets greater than or equal to 100 × 10⁹/L, and hemoglobin greater than or equal to 9 grams/deciliter (g/dL). * Hepatic: bilirubin less than or equal to 1.5 × the upper limit of normal (ULN); alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) less than or equal to 3.0 × ULN (ALP, AST, and ALT less than or equal to 5.0 × ULN is acceptable if the liver has tumor involvement). * Renal: calculated creatinine clearance (CrCl) greater than or equal to 45 milliliters/minute (mL/min). * For women: Must be surgically sterile, postmenopausal, or compliant with a medically approved contraceptive regimen during and for 6 months after the treatment period; must have a negative serum or urine pregnancy test within 7 days before study enrollment, and must not be breast-feeding. For men: Must be surgically sterile or compliant with a contraceptive regimen during and for 6 months after the treatment period. Exclusion Criteria: * Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. * Are receiving concurrent chronic systemic immune therapy, or chemotherapy for a disease other than cancer. * Concurrent administration of any other antitumor therapy. * Known prior allergic/hypersensitivity reaction to any of the components of the study treatment. * Serious concomitant systemic disorder (for example, active infection) or psychiatric disorder that, in the opinion of the investigator, would compromise the participant's ability to complete the study. * Have serious cardiac disease, such as symptomatic angina, unstable angina, or the history of myocardial infarction in the previous 12 months. * Second primary malignancy that is clinically detectable at the time of consideration for study enrollment. * Have had another primary malignancy other than HNC, unless that prior malignancy was treated at least 2 years previously with no evidence of recurrence. Exception: Participants with a history of in situ carcinoma of the cervix, nonmelanoma skin cancer, or low-grade (Gleason score less than or equal to 6) localized prostate cancer will be eligible even if diagnosed and treated less than 2 years previously. * Nasopharyngeal, paranasal sinus, lip, or salivary gland cancer. * Presence of clinically significant (by physical exam) third-space fluid collections; for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry. * Have peripheral neuropathy of Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or higher. * Have central nervous system (CNS) metastases (unless the participant has completed successful local therapy for CNS metastases and has been off corticosteroids for at least 4 weeks before starting study therapy). Brain imaging is required in symptomatic participants to rule out brain metastases, but is not required in asymptomatic participants. * Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose less than or equal to 1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam). * Unable or unwilling to take folic acid, vitamin B12, or prophylactic corticosteroids. * Recent (within 30 days before enrollment) or concurrent yellow fever vaccination.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Cycle 1: Week 1 - Cetuximab 400 milligrams/square meter (mg/m²) on Day 1; Pemetrexed 500 mg/m² on Day 1; Carboplatin area under curve (AUC) 5 on Day 1 or Cisplatin 75 mg/m² on Day 1 Week 2 - Cetuximab 250 mg/m² on Day 1 Week 3 - Cetuximab 250 mg/m² on Day 1 Cycle 2-6: Week 1 - Cetuximab 250 mg/m² on Day 1; Pemetrexed 500 mg/m² on Day 1; Carboplatin AUC 5 on Day 1 or Cisplatin 75 mg/m² on Day 1 Week 2 - Cetuximab 250 mg/m² on Day 1 Week 3 - Cetuximab 250 mg/m² on Day 1 Following Cycle 6, Cetuximab Monotherapy: 250 mg/m² intravenously weekly on Day 1
intervention Names
Drug: Pemetrexed
Drug: Cetuximab
Drug: Carboplatin
Drug: Cisplatin
label
Triplet Combination Therapy
type
EXPERIMENTAL

interventions

arm Group Labels
Triplet Combination Therapy
description
Administered intravenously, for maximum of 6 cycles.
name
Pemetrexed
other Names
Alimta
LY231514
type
DRUG
arm Group Labels
Triplet Combination Therapy
description
Administered intravenously in combination therapy, for a maximum of 6 cycles. After the completion of 6 cycles, participants who have not experienced disease progression will continue on cetuximab monotherapy until disease progression.
name
Cetuximab
other Names
Erbitux
type
DRUG
arm Group Labels
Triplet Combination Therapy
description
Administered intravenously, for a maximum of 6 cycles
name
Carboplatin
type
DRUG
arm Group Labels
Triplet Combination Therapy
description
Administered intravenously, for a maximum of 6 cycles
name
Cisplatin
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 69
type: ACTUAL

Registered outcome plans (not posted results)

other Outcomes

description
Presented are the number of participants who died due to adverse events (AEs) while on treatment and participants who died due to progressive disease (PD) during the 30-day post-treatment discontinuation FU.
measure
Number of Participants Who Died While on Treatment and Died During 30-Day Post-Treatment Discontinuation Follow-Up (FU)
time Frame
From enrollment to 30 days post-treatment discontinuation up to 26.4 months

primary Outcomes

description
PFS was defined as the duration from the date of enrollment to the first date of documented objective progressive disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD is ≥20% increase in sum of longest diameter of target lesions or the appearance of new lesions. For participants who were not known to have died or to have had objective PD at the time of the data inclusion cutoff, PFS was censored at their last objective progression-free disease assessment prior to the cutoff date or the date of initiation of subsequent systemic anticancer therapy.
measure
Progression-Free Survival (PFS)
time Frame
From enrollment to measured progressive disease up to 15.3 months (tumor assessments performed every other cycle during study treatment, and then every 6 weeks during follow-up)

secondary Outcomes

description
OS is defined as the duration from the date of enrollment to the date of death from any cause. For participants who were alive at the time of the data inclusion cutoff, OS was censored at the date of last contact prior to that cut-off date.
measure
Overall Survival (OS)
time Frame
From enrollment to the date of death from any cause up to 26.4 months (assessment completed during trial period at least every 3 months)
description
PR or CR is classified by the investigators according to RECIST criteria version 1.0. PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesions; CR is the disappearance of all target and non-target lesions. Percentage of participants having a PR or CR is calculated as a total number of participants with PR or CR from enrollment until disease progression or recurrence divided by the total number of participants treated, then multiplied by 100.
measure
Percentage of Participants Having a Confirmed Partial Response (PR) or Complete Response (CR)
time Frame
From enrollment to objectively determined progressive disease up to 15.3 months (tumor assessments performed every other cycle during study treatment until progressive disease)
description
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. A regression equation defines a utility value for these health states to generate an index score. The possible values for index score range from -0.594 (severe problems in all 5 dimensions) to 1 (no problem in all dimensions) on a scale where 1 represents the best possible health state. The EQ-5D Visual Analog Scale (VAS) is used to record a participant's rating for his/her current health-related quality of life state on the day of questionnaire administration and is captured on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state).
measure
Change From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L)
time Frame
Baseline, Day 1 of Cycles 2, 4, 6, cetuximab monotherapy Cycles 2 and 4 (21-day cycle)
description
PSS-HNC is a clinician-rated instrument designed to measure speaking and eating disabilities of participants with head and neck cancer and consists of 3 subscales: normalcy of diet (NOD) subscale measures the ability of the participants to eat a normal diet, subscale ranges from 0 (non-oral feeding) to 100 (unrestricted diet); understandability of speech (UOS) subscale measures the degree a clinician is able to understand the participant's speech, subscale ranges from 0 (never understandable) to 100 (always understandable); eating in public (EIP) subscale, rating based on the participant's response to the questions of whom he/she eats with and in what setting, subscale ranges from 0 (always eats alone) to 100 (no restriction of place, food, or companion). Change from baseline: negative value represents a decrease in function and a positive value represents an increase in function.
measure
Change From Baseline in Performance Status Scale for Head and Neck Cancer (PSS-HNC)
time Frame
Baseline, Day 1 of Cycles 2, 4, 6, cetuximab monotherapy Cycles 2 and 4 (21-day cycle)

Full study description

brief Summary: The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell carcinoma of the head and neck.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-2ce6063692d8e49fff26
requested nct id
NCT01087970
primary nct id
NCT01087970
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Parathyroid+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2b4988b513f0b70e7c49c0c10cabf5241c1231b8e29e89b78dc9406bd8749c8a
payload sha256
a7575f7d78700065120944b6f75ae6f93f85f715008a83be52ef232ab17f2f4e
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-2ce6063692d8e49fff26
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01087970
occurrences
context exact
NCT01087970
end
11
exact text
NCT01087970
start
0
offset unit
unicode_code_points
query cond
Parathyroid Cancer
query disease state id
ds-parathyroid-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-parathyroid-cancer-000.json
source file sha256
2b4988b513f0b70e7c49c0c10cabf5241c1231b8e29e89b78dc9406bd8749c8a
source json pointer
/studies/12/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
e8e1efbabe043b3f2bd91c7d48ee96a4d7c7749476b43a7dc20c3f8301c02b35
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Parathyroid+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-75f2e03d60c84108901f
requested nct id
NCT01087970
primary nct id
NCT01087970
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Laryngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
payload sha256
798f8aea80c74783ad9445b149f263c07ead7664162f4e595c2242854ef69de5
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-75f2e03d60c84108901f
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01087970
occurrences
context exact
NCT01087970
end
11
exact text
NCT01087970
start
0
offset unit
unicode_code_points
query cond
Laryngeal Cancer
query disease state id
ds-laryngeal-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
source file sha256
fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
source json pointer
/studies/78/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
e8e1efbabe043b3f2bd91c7d48ee96a4d7c7749476b43a7dc20c3f8301c02b35
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Laryngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice